Public health and carrageenan regulation: a review and analysis

Part of the Developments in Applied Phycology book series (DAPH, volume 2)


The status of carrageenan in the regulatory sphere influences how and where it may be used, with implications for seaweed farmers, carrageenan manufacturers and consumers. Over the period 1935 to the present the status of carrageenan has been effected by changes in the regulatory environment that reflect new understandings about carrageenan, health and health risks as well as broader trade, social and political changes. This paper reviews regulatory progress from the 1930s to the present. It reflects, in particular, the shifting priorities in public health and their effects on the regulatory status of carrageenan. Four case studies of public controversies about carrageenan safety are discussed in relation to regulatory responses and their public health significance. It is concluded that current assessments of risk associated with carrageenan have, in some contexts, failed to take into account the full spectrum of safety assessments that have been carried out and the maturing of food additive regulations thereby allowing a myth of risk to continue.


Carrageenan Degraded carrageenan Food regulation Health risk Poligeenan Public health 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Abramsson-Zetterberg L, Svensson K (2005) Semicarbazide is not genotoxic in the flow cytometry-based micronucleus assay in vivo. Toxicol Lett 155:211–217PubMedCrossRefGoogle Scholar
  2. AFC Panel (2005) Opinion of the scientific panel on food additives, flavourings, processing aids and materials in contact with foodon a request from the commission related to semicarbazide in food. EFSA J 219:1–36Google Scholar
  3. Ames BN, Gold LS (1997) Environmental pollution, pesticides, and the prevention of cancer: misconceptions [published erratum appears in FASEB J 1997 Dec;11(14):1330]. FASEB J 11:1041–1052PubMedGoogle Scholar
  4. Ames BN, Gold LS (1998) The causes and prevention of cancer: The role of environment. Biotherapy 11:205–220PubMedCrossRefGoogle Scholar
  5. Anderson W, Hargreaves GC (1965) Gastro-intestinal therapeutic. US Patent 3175942, March 13 1965Google Scholar
  6. Atkins PJ, Bowler IR (2000) Food in society: economy, culture, geography. Arnold, LondonGoogle Scholar
  7. Bixler HJ (1994) The carrageenan connection IV. Br Food J 96:12–17CrossRefGoogle Scholar
  8. Bixler HJ (1996) Recent developments in manufacturing and marketing carrageenan. Hydrobiologia 326/327:35–57CrossRefGoogle Scholar
  9. Borthakur A, Bhattacharyya S, Dudeja PK, Tobacman JK (2007) Carrageenan induces interleukin-8 production through distinct Bcl10 pathway in normal human colonic epithelial cells. Am J Physiol Gastrointest Liver Physiol 292:G829–G838PubMedCrossRefGoogle Scholar
  10. Buck CB, Thompson CD, Roberts JN, Müller M, Lowy DR, et al. (2006) Carrageenan is a potent inhibitor of Papillomavirus infection. PLoS Pathog 2(7): e69 doi:10.1371/journal.ppat.0020069
  11. Carthew P (2002) Safety of carrageenan in foods. Environ Health Perspect 110:A176PubMedGoogle Scholar
  12. Chapman VJ (1950) Seaweeds and their uses. 1st ed. Camelot Press, LondonGoogle Scholar
  13. Chapman J.(2001) Cancer food scare. Daily Mail October 27;Sect. V2:21Google Scholar
  14. Chopin T (1998) The seaweed resources of Eastern Canada. In: Critchley AT, Ohno M (eds.) Seaweed resources of the world. Japan International Cooperation Agency, Yokosuka, Japan, pp 273–302Google Scholar
  15. Cohen S, Ito N (2002) A critical review of the toxicological effects of carrageenan and processed Eucheuma seaweed on the gastrointestinal tract. Crit Rev Toxicol 32:413–444PubMedCrossRefGoogle Scholar
  16. Commission Directive (1995) Directive No. 95/2/EC and 96/85EC. Office for Official Publications of the European Communities [serial online]. Available via:
  17. Council of the Pharmaceutical Society of Great Britain (1911) The British Pharmaceutical Codex. The Pharmaceutical Press, LondonGoogle Scholar
  18. Coveney J (2003) Why food policy is critical to public health. Crit Public Health 13:99–105CrossRefGoogle Scholar
  19. de la Calle MB, Anklam E (2005) Semicarbazide: occurrence in food products and state-of-the-art in analytical methods used for its determination. Analytical and Bioanalytical Chemistry 382:968–977PubMedCrossRefGoogle Scholar
  20. Dean R (1989) Food additives: their regulatory status. In: Lewis RJ (ed.) Food additives handbook. Van Nostrand Reinhold, New York, pp 3–27Google Scholar
  21. European Commission (1992) Opinion of the scientific committee on food on carrageenan. Brussels: Health and Consumer Protection Directorate General. (SCF/CS/ADD/EMU/199 Final)Google Scholar
  22. European Food Safety Authority (2003) Press Release: EFSA gives update on semicarbazide: No reason to change current dietary habits including for babies. Precautionary action by industry recommended for baby foods. Available via: cited
  23. European Parliament and Council (1995) Directive No. 95/2/EC and 96/85EC. Office for Official Publications of the European CommunitiesGoogle Scholar
  24. Felter HW, Lloyd JU (1898) King’s American dispensatory. Ohio Valley Co., CincinnattiGoogle Scholar
  25. Fernandez-Romero JA, Thorn M, Turville SG, Titchen K, Sudol K, Li J et al. (2007) Carrageenan/MIV-150 (PC-815), a Combination Microbicide. Sex Transm Dis 34:9–14PubMedCrossRefGoogle Scholar
  26. Food and Drug Administration (1958) Federal food, drug, and cosmetic act: Chapter II - Definitions. Sec. 201. [321]Google Scholar
  27. Food and Drug Administration.(2004) Code of Federal Regulations: CFR Title 21 Database. Available via: cited September 8 2004
  28. Food and Drug Administration (2006) Part 172 - food additives permitted for direct addition to food for human consumption. Code of Federal Regulations, USAGoogle Scholar
  29. Garrett ES, Jahncke ML, Cole EA (1998) Effects of Codex and GATT. Food Control 9:177–182CrossRefGoogle Scholar
  30. Greig JB (1999) Carrageenan. Geneva. World Health Organisation: WHO safety evaluation of certain food additives. (Food Additive Series 42)Google Scholar
  31. Hoenicke K, Gatermann R (2006) How can zero tolerances be controlled? The case study of Nitrofurans. Accreditation and quality assurance. J Qual Comparabili Reliabil Chem Meas 11:29–32Google Scholar
  32. Hoenicke K, Gatermann R, Hartig L, Mandix M, Otte S (2004) Formation of semicarbazide (SEM) in food by hypochlorite treatment: is SEM a specific marker for nitrofurazone abuse? Food Additives & Contaminants 21:526–537CrossRefGoogle Scholar
  33. Informatics Inc (1972) Monograph on carrageenan. Maryland: Submitted under contract to the Food and Drug AdministrationGoogle Scholar
  34. JECFA (1974) Seventeenth report of the joint FAO/WHO Expert committee on food additives, WHO Technical Series, No. 539Google Scholar
  35. JECFA (2001) Evaluation of certain food additives specifications. Addendum 9. Joint FAO/WHO expert committee on food additives, WHO Technical Report series, No.891Google Scholar
  36. Lang T (1999) The complexities of globalization: The UK as a case study of tensions within the food system and the challenge to food policy. Agric Human Values 16:169–185CrossRefGoogle Scholar
  37. Lewis JG, Stanley NF, Guist GG (1988) Commercial production and application of algal hydrocolloids. In: Lembi CA, Waaland JR (eds.) Algae and human affairs. Cambridge University Press, Cambridge, pp 205–236Google Scholar
  38. Livermore MA (2006) Authority and legitimacy in global governance: Deliberation, institutional differentiation, and the codex alimentarius. New York University Law Review 81(2):766–801Google Scholar
  39. London Food Commission (1988) Food adulteration and how to beat it. Unwin, LondonGoogle Scholar
  40. Marcus AJ, Watt J (1969) Ulcerative colitis in the guinea-pig caused by seaweed extract. J Pharmaceut Pharmacol 21:187Google Scholar
  41. Marinalg International (2003) Position statement on carrageenan and semicarbazide: EC alert notification 2003/201. Available via: cited April 15 2007
  42. McHugh DJ (2003) A guide to the seaweed industry. Rome: FAO Fisheries Technical Paper No. 441Google Scholar
  43. Merrill RA (1997) Food safety regulation: reforming the Delaney Clause. Annu Rev Public Health 18:313–340PubMedCrossRefGoogle Scholar
  44. Millstone E, Van Zwanenberg P (2002) The evolution of food safety policy-making institutions in the UK, EU and Codex Alimentarius. Soc Policy Adm 36:593–609CrossRefGoogle Scholar
  45. Murphy E (2004) Risk, maternal ideologies and infant feeding. In: Williams L, Germov J (eds.) The social appetite: an introduction to the sociology of food and nutrition. Oxford University Press, Melbourne, pp 200–219Google Scholar
  46. Noah L (1999) Legal aspects of the food additive approval process, in enhancing the regulatory decision-making approval process for direct food ingredient technologies: workshop summary. Institute of Medicine (IOM), Washington DCGoogle Scholar
  47. Noah L, Merrill RA (1998) Starting from scratch? Reinventing the food additive approval process. Boston University Law Review 78:329–443Google Scholar
  48. Piper D, Fenton B (1961) Effect of a sulfated polysaccharide on peptic digestion. A study in vitro of carrageenin (Ebimar). Gastroenterology 40:638–643PubMedGoogle Scholar
  49. Population Council (2006) Microbicide Program. Available via: cited 15 September 2006
  50. Scientific Committee on Food (2003a) Opinion of the Scientific Committee on Food on carrageenan. Brussels: European Commission; 5 March. (SCF/CS/ADD/EMU/199 Final)Google Scholar
  51. Scientific Committee on Food (2003b) Report of the scientific committee on food on the revision of essential requirements of infant formulae and follow-on formulae. European Union.Google Scholar
  52. Shah ZC, Huffman FG (2003) Current availability and consumption of carrageenan-containing foods. Ecol Food Nutr 42:357–371CrossRefGoogle Scholar
  53. Smit AJ (2004) Medicinal and pharmaceutical uses of seaweed natural products: A review. J Appl Phycol 16:245–262CrossRefGoogle Scholar
  54. Stanley N (1987) Production, properties and uses of carrageenan. In: McHugh DJ (ed.) Production and utilization of products from commercial seaweeds, vol 288. FAO, RomeGoogle Scholar
  55. Tobacman JK (1998) (Effects of lambda-carrageenan on human mammary myoepithelial cells and relation to mammary carcinogenesis). In: International symposium on the impact of biotechnology on prediction, prevention and treatment of cancer. Nice, FranceGoogle Scholar
  56. Tobacman JK (2001) Review of harmful gastrointestinal effects of carrageenan in animal experiments. Environ Health Perspect 109:983–994PubMedCrossRefGoogle Scholar
  57. Tobacman JK, Wallace RB, Zimmerman MB (2001a) Consumption of carrageenan and other water-soluble polymers used as food additives and incidence of mammary carcinoma. Med Hypotheses 56:589–598CrossRefGoogle Scholar
  58. Tobacman JK, Walters KS (2001b) Carrageenan-induced inclusions in mammary myoepithelial cells. Cancer Detec Prev 25:520–526PubMedGoogle Scholar
  59. Tomarelli RM, Tucker Jr WD, Bauman LM, Savini S, Weaber JR (1974) Nutritional quality of processed milk containing carrageenan. J Agric Food Chem 22:819–824PubMedCrossRefGoogle Scholar
  60. Veggeland F, Borgen SB (2005) Negotiating international food standards: The World Trade Organization’s impact on the Codex Alimentarius commission. Governance 18:675–708CrossRefGoogle Scholar
  61. Vogel D (2001) Ships passing in the night: The changing politics of risk regulation in Europe and the United States RSCAS working papers: EUI RSC 2001/16Google Scholar
  62. Weiner ML, Nuber D, Blakemore WR, Harriman JF, Cohen SM (2007) A 90-day dietary study on kappa carrageenan with emphasis on the gastrointestinal tract. Food Chem Toxicol 45:98–106PubMedCrossRefGoogle Scholar
  63. Weisburger JH (1994) Does the delaney clause of the U.S. food and drug laws prevent human cancers? Toxicol Sci 22:483–493CrossRefGoogle Scholar
  64. Wolf JH (2003) Low breastfeeding rates and public health in the United States. Am J Public Health 93(12):2000–2010PubMedCrossRefGoogle Scholar
  65. World Health Organization (2007) Semicarbazide. Available via: cited April 18 2007
  66. Yuan H, Song J, Li X, Li N, Dai J (2006) Immunomodulation and antitumor activity of [kappa]-carrageenan oligosaccharides. Cancer Lett 243:228–234PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science + Business Media B.V. 2007

Authors and Affiliations

  1. 1.Institute of Health and SocietyNewcastle UniversityNewcastle upon TyneUK

Personalised recommendations